NCT03692403

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

Conditions

• Endometriosis-related Pain

Interventions

Type	Name	Description
DRUG	Quinagolide 360 µg	Vaginal ring containing quinagolide 360 µg for daily releases
DRUG	Quinagolide 720 µg	Vaginal ring containing quinagolide 720 µg for daily releases
DRUG	Quinagolide 1080 µg	Vaginal ring containing quinagolide 1080 µg for daily releases
DRUG	Placebo	Matching placebo

Timeline

• Start date: 2018-12-26
• Primary completion: 2022-02-14
• Completion: 2022-02-14
• First posted: 2018-10-02
• Last updated: 2023-08-18
• Results posted: 2023-08-18

Locations

43 sites across 1 country: United States

Regulatory

• FDA-regulated drug study